Recent evidence from a meta-analysis, which included eight large randomized controlled trials, showed that PCSK9 inhibitors effectively reduced the risk of major cardiovascular events (MACE) and improved lipid profiles in patients with diabetes and dyslipidaemia over a median follow-up of 51 weeks [42]. This evidence concerns the gene PCSK9 and diabetes mellitus.